This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2016 Jun;136(6):1281-1283.

doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

Joerg Wenzel¹, Nadine van Holt², Judith Maier², Maria Vonnahme³, Thomas Bieber², Dominik Wolf³

Affiliations

Affiliations

¹ Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany. Electronic address: joerg.wenzel@ukb.uni-bonn.de.
² Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
³ Medical Clinic 3, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.

PMID: 26916391
DOI: 10.1016/j.jid.2016.02.015

Free article

Case Reports

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

Joerg Wenzel et al. J Invest Dermatol. 2016 Jun.

Free article

. 2016 Jun;136(6):1281-1283.

doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

Authors

Joerg Wenzel¹, Nadine van Holt², Judith Maier², Maria Vonnahme³, Thomas Bieber², Dominik Wolf³

Affiliations

¹ Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany. Electronic address: joerg.wenzel@ukb.uni-bonn.de.
² Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
³ Medical Clinic 3, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.

PMID: 26916391
DOI: 10.1016/j.jid.2016.02.015

No abstract available

PubMed Disclaimer

Similar articles

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C, Frémond ML, Bessis D, Carbasse A, Rice GI, Bondet V, Duffy D, Chatenoud L, Blanche S, Crow YJ, Neven B. Briand C, et al. Ann Rheum Dis. 2019 Mar;78(3):431-433. doi: 10.1136/annrheumdis-2018-214037. Epub 2018 Oct 3. Ann Rheum Dis. 2019. PMID: 30282666 No abstract available.
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
Klaeschen AS, Wolf D, Brossart P, Bieber T, Wenzel J. Klaeschen AS, et al. Exp Dermatol. 2017 Aug;26(8):728-730. doi: 10.1111/exd.13253. Epub 2017 May 3. Exp Dermatol. 2017. PMID: 27892610
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B, Biray Avci C. Goker Bagca B, et al. Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20. Cytokine Growth Factor Rev. 2020. PMID: 32636055 Free PMC article. Review.
Ruxolitinib.
Becker H, Engelhardt M, von Bubnoff N, Wäsch R. Becker H, et al. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. Recent Results Cancer Res. 2014. PMID: 24756798 Review.
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K, Sarlis NJ, Gupta V. Vaddi K, et al. Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Expert Opin Pharmacother. 2012. PMID: 23051187 Review.

See all similar articles

Cited by

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report.
Hu W, Zhang S, Lian C. Hu W, et al. Clin Cosmet Investig Dermatol. 2023 Oct 9;16:2793-2800. doi: 10.2147/CCID.S419344. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37841060 Free PMC article.
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.
Nikolopoulos D, Parodis I. Nikolopoulos D, et al. Front Med (Lausanne). 2023 Jun 29;10:1217147. doi: 10.3389/fmed.2023.1217147. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37457579 Free PMC article. Review.
Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus.
Huo R, Huang X, Yang Y, Lin J. Huo R, et al. J Inflamm Res. 2023 Apr 6;16:1471-1478. doi: 10.2147/JIR.S397639. eCollection 2023. J Inflamm Res. 2023. PMID: 37051062 Free PMC article. Review.
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P, Cardoneanu A, Burlui AM, Macovei LA, Bratoiu I, Buliga-Finis ON, Rezus E. Richter P, et al. Int J Mol Sci. 2022 Oct 4;23(19):11788. doi: 10.3390/ijms231911788. Int J Mol Sci. 2022. PMID: 36233087 Free PMC article. Review.
An update on the management of refractory cutaneous lupus erythematosus.
Verdelli A, Corrà A, Mariotti EB, Aimo C, Ruffo di Calabria V, Volpi W, Quintarelli L, Caproni M. Verdelli A, et al. Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213629 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations
- scite Smart Citations
Medical
- Genetic Alliance
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal